Global Biopharmaceutical Company Bristol Myers Squibb is in Munich, Upper Bavaria, Bavaria, Germany, on April 13, 2025. (Photo by Michael Nguyen/NurPhoto via Getty Images)NurPhoto via Getty ImagesBristol-Myers Squibb (NYSE: BMY) has considerably lagged behind the overall market, with its stock decreasing by 20% this year, while the S&P 500 index has risen by 14%. This drop can be attributed in part to recent challenges in the company’s drug pipeline, including underwhelming late-stage results for its cardio ...